Matthias Liechti | |
|---|---|
| Born | May 27, 1970 |
| Alma mater | University Hospital of Zurich, University of California San Diego, Scripps Research, University Hospital Basel |
| Occupation | Academic |
| Years active | 1998–present |
| Organization(s) | University Hospital Basel, MindMed |
| Known for | Studying psychedelics, entactogens, and other psychoactive drugs |
| Website | biomedizin universe biomedizin |
Matthias Emanuel Liechti (born 27 May 1970) is a Swiss scientist and physician who studies psychedelics, entactogens, and other psychoactive drugs. [1] [2] He is the head of the Liechti Lab at the University of Basel in Switzerland. [1] [3] The lab conducts in-vitro research, animal studies, and clinical studies of psychoactive drugs. [3] They have conducted clinical studies of drugs including LSD, psilocybin, mescaline, dimethyltryptamine (DMT), and MDMA. [2] The lab also characterizes novel psychoactive substances (designer drugs). [2]
Liechti is a professor of clinical pharmacology and internal medicine and an attending physician at the University of Basel. [1] He attended and underwent training at the University of California, San Diego and the University Hospital of Zurich, among other institutions. [1]
In April 2020, the Liechti Lab entered an agreement and long-term partnership with the psychedelic pharmaceutical company MindMed such that MindMed would have exclusive rights to the lab's data, compounds, and patent rights. [1] [3] One such project is a psychedelic "neutralizer" technology that can abort or shorten a psychedelic experience. [1] [3] [4] [5]
Uniquely in Europe, certain psychedelics and entactogens including LSD, psilocybin, and MDMA have been legal for medical use in Switzerland, where Liechti and his lab are based, since 2014. [6]